© November 2025 | IJIRT | Volume 12 Issue 6 | ISSN: 2349-6002

Ai In Pharma: A Review of Benefits, Applications and Future Directions

Miss. Sakshi Y. Badki[1], Mr. Lalit H. Jambhulkar[2], Mr. Ashutosh V. Khadatkar[3], Dr. Nilesh O. Chachda[4]
[1,2,3,4]*S.C.S.M.S.S. Institute of Pharmacy, Maregaon, Maharashtra, India*

Abstract— **Artificial Intelligence (AI) has revolutionized drug development, quality assurance, and discovery in the pharmaceutical manufacturing sector. This study examines AI's critical role in improving productivity, efficiency, and accuracy in a variety of fields, such as digital therapy, clinical trials, disease identification, personalized treatment, and manufacturing optimization. Predictive analytics, automation, and real-time decision-making are made possible by artificial intelligence (AI), which drastically cuts costs and development times by utilizing machine learning (ML), deep learning (DL), and neural networks. AI's practical applications are illustrated by case studies like DeepMind's AlphaFold and Benevolent AI COVID-19 drug repurposing. The study comes to the conclusion that automation, data-driven insights, and human-machine cooperation will converge in pharmaceutical manufacturing in the future, opening the door to more efficient, patient-centered, and long-lasting healthcare solutions.**

Index Terms— **Artificial Intelligence (AI), Pharmaceutical Industry Drug Discovery, Machine Learning (ML), Deep Learning (DL) Predictive Analytics, Personalized Medicine, Quality Control, Clinical Trials, Drug Development, Automation, Data-Driven, Decision Making.**

I. INTRODUCTION

The imitation of human intellect in computers designed to carry out activities that would otherwise need higher-level cognitive skills is known as artificial intelligence (AI). Problem solving, learning, planning, natural language processing, and picture analysis and interpretation are among the tasks that will be covered.(1) The study examines the critical role that artificial intelligence (AI) plays in pharmaceutical manufacturing, highlighting its enhancement of quality control procedures and support for informed decision-making. (4)

Fig 1: AI in the pharmaceutical industry

AI's use in the pharmaceutical industry isn't new; computational methods have been key for years. Computer-aided drug design started in the 1970s. By the early 1980s, computers were used solely to design drugs. Today, computational methods help screen chemical libraries.

New areas for AI in pharmacy include drug discovery, delivery formulation, and other healthcare uses. The hype has turned into real hope. AI models can predict in vivo reactions, therapeutic pharmacokinetics, and optimal dosages, among other things. (8)





Fig 2: History of AI in Pharmacy

II. ROLE OF ARTIFICIAL INTELLIGENCE (AI) IN THE FOLLOWING AREAS

2.1 Customized care and digital therapy:
Through wearable patient monitoring, AI-powered digital medicines, and the analysis of large datasets to develop individualized treatment regimens, AI improves personalized care and digital therapy. In order to customize medical interventions and improve pharmaceutical dosages, it examines patient data, such as genetics, lifestyle, and preferences. (40)

2.2 Treatment with radiation:
By automating and streamlining the treatment planning process, increasing precision, and customizing patient care, artificial intelligence (AI) significantly contributes to radiation therapy. Its uses include helping with quality assurance, producing high-quality treatment plans more quickly.

2.3 The retina:
The ultimate goal of improving patient outcomes and treatment accessibility, its applications include early detection, enhanced diagnostic accuracy by spotting minor abnormalities, and higher efficiency through scalable screening.

2.4 Drug research:
Artificial intelligence (AI) helps with medication repurposing, improves clinical trial efficiency, and personalizes medicine by matching individuals to therapies.

2.5 Prediction of bioactivity and toxicity:
AI models can predict toxicity by predicting negative effects, organ damage, and other dangers based on a compound's structure and other attributes, they can also predict bioactivity by identifying prospective targets and evaluating a drug's affinity for them.

2.6 Research studies:
Researchers can become more efficient and make discoveries more quickly by using AI tools to assist with literature reviews, experimental design, and information synthesis. Nonetheless, human control is still essential to guaranteeing the correctness, uniqueness, and integrity of study findings. (3)

III. APPLICATIONS OF AI IN THE PHARMACEUTICAL INDUSTRY

AI methods play a key role in identifying and minimizing tablet flaws, improving production quality control. Furthermore, AI helps reduce drug toxicity and errors in the early stages of the drug development process, anticipates interactions between chemicals and proteins, and facilitates the production of capsule-based formulations that fulfill strict criteria.(38)

Fig 3: Application of AI in different pharmaceutical domain

3.1 Research and development
Pharmaceutical companies must conduct research and trials during the time-consuming and expensive drug discovery process. Machine learning (ML) expedites the process by sifting through the massive amount of chemical and biological data.

3.2 Clinical trials
The application of artificial intelligence (AI) approaches to enhance patient recruitment and selection procedures. A more complete patient characterisation is made possible by these AI-

powered systems' ability to collect and evaluate data from multiple clinical trial centers at once. Currently, only around one-third of Phase II trial chemicals advance to Phase III. These investigations cost billions of dollars and take ten to fifteen years to finish. Ineffective studies also result in missed preclinical development expenses. (21)

3.3 Manufacturing Process

By using AI in pharmaceutical product manufacturing, businesses can increase productivity and product quality while simplifying operations, cutting costs, achieving high quality standards, and guaranteeing stability in production processes. AI's ability to track and make real-time modifications is essential to stable and predictable production processes, which in turn improves pharmaceutical product quality by quickly identifying and fixing problems. (20)

3.4 Drug development

AI can replace the traditional method of trial and error in this situation. Numerous computational methods, including QSPR, can be used to address formulation design problems like instability, dissolving, porosity, and many more. Using rule-based algorithms, decision-making systems select the type, and quantity of excipients based on the physicochemical characteristics of the drug. (5) It can increase its efficacy and efficiency, which will help everyone—from businesses creating novel medications. (25)

3.5 Drug formulation

Other formulations, including solid dispersions, extrudates, pellets, nanoparticles, and liposomes, have emerged in pharmaceutical sciences in addition to traditional dosage forms. These techniques are called "formulation techniques" because they make it easier to create formulations or give commonly used dosage forms, like tablets, additional functionality. AI applications in formulation techniques can successfully address a variety of API issues, including low solubility, stability, bioavailability, and production capability.

3.6 AI for Drug Delivery

The pharmaceutics industry's integration of AI and big data has led to computational pharmaceutics, which employs multiscale modeling techniques to enhance medication delivery procedures. Artificial intelligence (AI) systems can examine complex relationships between pharmacological properties, formulation ingredients, and physiological parameters to predict drug behavior at every scale. (5) In order to increase precision in drug targeting and reduce side effects while increasing efficacy, artificial intelligence helps develop tailored drug delivery systems and forecast interactions between nanoparticles and biological systems. (40)

3.7 Bioavailability of poorly water-soluble drugs

Using supersaturating drug delivery systems (SDDS), artificial intelligence (AI) holds great potential for increasing the oral bioavailability of medications that are poorly soluble in water. AI can improve medication availability and solubility by optimizing SDDS formulation factors such as carrier materials and release rates. Additionally, appropriate precipitation inhibitors (also known as "parachutes") can be found using AI-based predictive models. (38)

3.8 AI in tablet defects

Defects in appearance and functional aspects can result from flaws such lamination, variations in hardness, and weak bonding. Defects in content nonuniformity affect dose consistency. Significant flaws such as sticking, mottling, swelling, double impression, and softening may cause the quality to decline. Therefore, quality control procedures are crucial to the production of safe and efficient tablets an artificial intelligence (AI) method, such as a convolutional neural network (CNN), can be used to guarantee all the requirements needed for automated investigation of tablet flaws. (38)

3.9 AI in drug discovery

In the drug development process, it takes a lot of time to test compounds against samples of sick cells. To determine which compounds are physiologically active and deserving of more research, more examination is required. Novartis's research teams predict which untested substances may merit more study by using images produced by machine learning systems. New and effective drugs can be made available sooner and at a lesser cost than when each chemical is examined by hand, even when computers find new data sets faster than traditional human analysis and laboratory trials. (36)



Fig 4: AI Predictive modeling in personalized Medicines (17)

IV. BENEFITS OF AI IN THE PHARMACEUTUCAL INDUSTRY

4.1 Improved Efficiency and Productivity

Significant efficiency benefits have been achieved by integrating AI into pharmaceutical operations. According to recent research, 95% of pharmaceutical companies report investing in AI skills, and 80% of specialists in the life sciences and pharmaceutical industries use AI for drug discovery. Drug discovery procedures can now be shortened from five to six years to just one year thanks to AI technology, which represents a revolutionary increase in productivity.

4.2 Enhanced Accuracy and Precision

Complex datasets are easily processed by AI systems, which can also spot patterns that human analysis would overlook. Computer vision systems offer reliable, impartial analysis free from human subjectivity and tiredness in quality control applications. By combining several data types, such as genetic, clinical, and lifestyle characteristics, predictive models for treatment responses are able to reach improved accuracy rates.

4.3 Accelerated Timelines and Reduced Costs

AI-enhanced clinical trials have the potential to save 70% of costs and 80% of time. Better patient recruiting, real-time monitoring, and predictive analytics that avoid expensive protocol changes are the main causes of the acceleration. AI-enabled workflows in drug discovery can save 30% on expenses and 40% on time to preclinical candidates.

4.4 Superior Decision-Making Through Predictive Analytics

AI's sophisticated prediction skills enable pharmaceutical companies to make proactive decisions instead of reactive ones. Predictive maintenance eliminates equipment failures in manufacturing before they affect output. Predictive models in clinical development increase success rates by identifying patients who are most likely to benefit from therapies. Pharmacovigilance systems anticipate possible safety concerns before they become serious ones.

4.5 Cost Reduction and Resource Optimization

AI reduces human error and automates labor-intensive operations, which results in significant cost savings. through cost reductions in all pharmaceutical activities. Regulatory compliance monitoring, quality control inspections, and automated document processing all increase accuracy while lowering the need for human resources. Through the identification of the most promising research lines and the avoidance of costly errors, predictive analytics optimizes the allocation of resources. (15)

V. CASE STUDY AND EXAMPLES OF AI

Case examples from the real world demonstrate how AI is actively changing the drug discovery process. These success stories demonstrate how top innovators are using AI to address pressing issues and expedite outcomes.



Fig 5: Examples of AI Application in pharmaceutical industry

5.1 DeepMind: Structural Biology Revolution with Alpha Fold

Alpha Fold 2 is an AI system developed by DeepMind that can accurately predict protein shapes at the atomic level. It was released in 2020. As one of the most significant scientific discoveries of the decade, this invention resolved a biological problem that had existed for fifty years, according to the journal NatureDeeper applications in drug design are made possible by Alpha Fold 3, its successor, which further models' protein-ligand interactions. Target validation and ligand docking in drug discovery pipelines around the world are being revolutionized by these techniques.

5.2 Benevolent AI: Drug Repurposing During the COVID-19 Crisis
Benevolent AI used their in-house AI platform to conduct large-scale biomedical data and literature analysis in an effort to identify potential COVID-19 therapeutic options. Around the start of 2020, it identified baricitinib, a JAK inhibitor used to treat rheumatoid arthritis, as a potential means of reducing virus access into cells. Following clinical research, the FDA and WHO approved baricitinib for use in hospitalized COVID-19 patients, granting it Emergency Use-Authorization. By processing millions of scientific papers and molecular interaction data in a matter of days, the AI platform aided in streamlining the process of generating hypotheses. The real-world speed advantage AI provides in urgent therapeutic discovery was proved by Benevolent AI's methodology. The case turned into a historic illustration of AI effectively directing medication repurposing in the face of a worldwide health crisis.

VI. CHALLENGES AND LIMITATIONS OF AI IN PHARMACEUTICAL INDUSTRY

AI's incorporation into the pharmaceutical sector has completely changed every aspect of the business, from patient care to production and drug research. But these developments have also brought with them a number of difficulties and restrictions, which prevent a smooth implementation. How secure and consumable the data is is one of the biggest obstacles. In the pharmaceutical business, patient data is frequently crucial to the functioning of an AI application. As a result, the systems are probably going to be the focus of hackers who want to get unauthorized access and compromise data. (17)

6.1 Data Quality and Quantity:
Large, high-quality datasets are necessary for AI models to efficiently identify patterns. It might be difficult to find adequate and trustworthy data, particularly in specialist fields.

6.2 Data Privacy and Security:
To prevent breaches, strong security measures are required when managing proprietary and private patient data and guarantee adherence to data protection laws. Regulatory Obstacles: Adherence to regulatory norms, which can be challenging because of changing guidelines, is necessary when integrating AI technology into pharmaceutical manufacturing. (32)

6.3 Risks of Over dependence on AI Applications:
Even while AI is capable of rapid data analysis and pattern recognition, errors can still occur. errors that arise when the algorithm is flawed, the data is inaccurate, or the system is unable to identify particular circumstances. Over-reliance on AI without adequate human oversight may lead to inaccurate and incorrect decisions, which could compromise patient safety. Thus, AI technology is devoid of human feelings and discernment. They might not take into account a patient's emotional requirements or personal preferences, which are crucial when making healthcare decisions. (16)

6.4 Change Management:
Organizational culture may need to alter in order to implement AI-driven improvements, which could cause opposition or make it difficult for new technologies to be adopted.

6.5 Integration:
Coordination between IT and manufacturing teams is necessary for the complicated integration of AI systems with current production processes and infrastructure. Careful planning, professional collaboration, and a clear strategy are necessary to successfully integrate AI into pharmaceutical manufacturing processes while balancing these advantages and difficulties.

6.6 Data quality and availability:
The availability of high-quality annotated datasets for model training is a major obstacle in AI-powered drug development. One major obstacle is data

heterogeneity, which occurs when data originates from many sources including chemical structures, biological testing, and clinical investigations. Integration can be challenging and time-consuming and harmonize these various data sources into a single format for AI training. (32)

6.7 Interpretability and transparency:
he inherent complexity and opacity of AI systems pose a serious obstacle to their mainstream adoption. Many AI models, particularly DNNs, function as "black boxes," making it challenging to comprehend the reasoning behind their decisions. Concerns of trust, accountability, and the potential for unintentional bias are raised by the lack of interpretability and openness. For example, in order to make educated judgments and guarantee patient safety, healthcare professionals must comprehend the logic behind an AI-powered diagnosis.

6.8 Integration into existing drug development processes:
There are many obstacles to overcome when integrating AI techniques into current drug development pipelines. Rigid procedures and a heavy focus on tried-and-true techniques are common features of traditional pharmaceutical operations. It might be necessary to make considerable adjustments to the current workflows, infrastructure, and knowledge in order to integrate AI. Adoption of these technologies may also be hampered by worries about intellectual property, data privacy, and the possible effects of AI on jobs in the pharmaceutical sector. (32)

6.9 Validation and Testing:
To guarantee the security and effectiveness of AI models, extensive testing and validation are required, which can be a time-consuming and resource-intensive procedure. Regulators occasionally require reassurance that these improvements won't pose new hazards. (32)

VII. DIFFICULTIES IN ADOPTING AI IN PHARMA

7.1 Unfamiliarity with the technology:
Many pharmaceutical organizations are reluctant to embrace and implement AI because they see it as a "black box" because of its infancy and complexity.

7.2 Inadequate IT infrastructure:
Because AI was not originally considered when developing current IT systems and infrastructure, it is challenging for pharmaceutical companies to integrate AI with ease. Therefore, it will be necessary to make large financial investments in order to upgrade the IT infrastructure.

7.3 Unstructured data:
It takes more effort to organize and transform the pharmaceutical industry's data into a format suitable for AI analysis because a significant portion of the data is available in free text format. (21)

VIII. FUTURE DIRECTION AND OPPORTUNITY

AI in pharmaceutical manufacturing has a bright future ahead of it, with ground-breaking developments set to revolutionize the sector. Many significant perspectives on AI's role in the pharmaceutical manufacturing sector emerge as technology develops and capabilities expand:
8.1 Drug Development and Personalized Medicine:
AI will revolutionize medical research by enabling the development of personalized medications based on each patient's distinct characteristics. AI will choose the best course of action by examining genetic, health, and lifestyle data, leading to more individualized and efficient treatments.

8.2 Accelerated Drug Discovery:
By quickly searching through enormous chemical libraries for possible candidates, AI-driven simulations and prediction models will expedite the process of finding new drugs. As a result, the time and cost associated with bringing new drugs to market will be significantly reduced.

8.3 Constant Optimization of Manufacturing:
AI will be crucial for optimizing processes in real time, which will guarantee that manufacturing operations operate as efficiently as possible while upholding stringent quality control. Predictive analytics and automated changes will cut expenses, minimize waste, and enhance overall production results.

8.4 Superior Quality Assurance:
AI-powered quality control systems will become more sophisticated, capable of spotting even the tiniest

defects and ensuring compliance with the most stringent legal requirements. This will lessen the need for manual checks while improving the quality and safety of the product.

8.5 Auditing and Regulatory Compliance:
By automating the processes of documentation, record-keeping, and auditing, artificial intelligence (AI)-driven platforms will simplify regulatory compliance. This would guarantee that manufacturing facilities for pharmaceuticals continue to adhere to changing industry requirements and laws.

8.6 Auditing and Compliance with Regulations:
Digital twins, which are virtual versions of actual industrial processes, will be used more frequently. These digital twins will be used by AI to model and optimize manufacturing, anticipate possible problems, and test novel ideas before they are implemented.

8.7 IoT and AI integration:
A smooth network of connected sensors and equipment will be produced by combining AI with Internet of Things (IoT) devices. AI will examine data from these devices in real time to check equipment health, optimize procedures, and guarantee constant product quality.

8.8 Supply Chain Optimization:
Artificial intelligence will improve pharmaceutical supply chains by predicting demand, monitoring inventory levels, and anticipating any disruptions. This will ensure the timely and efficient distribution of pharmaceutical products.

8.9 Regulatory Compliance and Safety:
By guaranteeing rigorous adherence to regulatory criteria throughout the production process, AI will increase patient security. This will lessen the likelihood of contamination, errors, and deviations from recognized standards.

8.10 Human-Machine Cooperation:
Instead of replacing human capabilities, AI in pharmaceutical manufacturing aims to improve them. Innovation and decision-making will be more intelligent when human experience and AI-driven insights are merged. Moral Points to Remember: Ethical concerns like data privacy, bias mitigation, openness, and accountability will become crucial as AI plays increasingly important roles in pharmaceutical manufacturing. Personalized medication, improved quality control, faster drug development, and better efficiency are the main characteristics of AI's future in pharmaceutical manufacturing. (14)

TABLE 1: - Comparison of AI in pharmaceutical manufacturing & Traditional manufacturing

Aspect	AI In Pharmaceutical Manufacturing	Traditional Pharmaceutical Manufacturing
Control of Quality	Highly accurate fault identification and analysis.	manual that checks for possible mistakes.
Efficiency	Automated processes and reduced human intervention	Labour intensive processes
Real time Monitoring	Continuous monitoring and rapid response to deviations	Periodic checks and delayed responses
Personalised Medicines	Tailored treatments based on individual for all patient characteristics	Standard treatments for all patients
Risk Mitigation	Early detections of deviations and defects	Relying on post-production inspections
Innovation	Facilitates innovation through data driven discoveries.	Limited scope for innovation

IX. CONCLUSION

Artificial Intelligence has emerged as a transformative force in the pharmaceutical industry, revolutionizing every stage from drug discovery and development to manufacturing, quality control, and patient care. By leveraging advanced data analytics, machine learning, and predictive modelling, AI accelerates drug discovery, enhances clinical trials, ensures precision manufacturing, and promotes personalized medicine. The technology enables faster decision-making, reduces costs, and improves accuracy and efficiency across operations.However, the widespread adoption of AI also brings challenges, including data privacy concerns, model transparency issues, regulatory complexities, and the need for skilled professionals and strong IT infrastructure. Overcoming these barriers through robust governance, ethical AI practices, and cross-disciplinary collaboration will be crucial. Looking forward, the integration of AI with technologies like IoT, digital twins, and big data analytics promises to reshape pharmaceutical innovation, creating smarter, safer, and more patient-centric healthcare systems. AI is not replacing human expertise but augmenting it—paving the way for a future where medicine is more efficient, personalized, and accessible to all.

REFERENCE

[1] Fröling, E., Rajaeean, N., Hinrichsmeyer, K. S., Urban, J. N., & Lenz, C. (2024). Artificial Intelligence in Medical Affairs: A New Paradigm with Novel Opportunities. Pharmaceutical Medicine, 38(5), 331–342. https://doi.org/10.1007/s40290-024-00536-9 (link.springer.com)

[2] Kampanart, H., Burapapadh, K., Ganokratanaa, T., Suwanpitak, K., Kraisit, P., Sriamornsak, P., & Sangnim, T. (2025). [Article title in italics]. [Journal Name], [volume(issue)], pages. https://doi.org/xxxx

[3] Singh, N., Kumar, S., Prabhu, K., Shukla, A., & Yadav, A. (2024). A review on artificial intelligence in pharma. International Journal of Pharmaceutical Sciences Review and Research, 84(1), 33–39. https://doi.org/10.47583/ijpsrr.2024.v84i01.006

[4] Saha, G. C., Eni, L. N., Saha, H., Parida, P. K., Rathinavelu, R., Jain, S. K., & Haldar, B. (2023). Artificial intelligence in pharmaceutical manufacturing: Enhancing quality control and decision making. Rivista Italiana di Filosofia Analitica Junior, 14(2), 116–126. https://doi.org/10.13140/RG.2.2.10252.39041

[5] Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics, 15(7), 1916. https://doi.org/10.3390/pharmaceutics15071916

[6] Kaul, V., Enslin, S., & Gross, S. A. (2020). History of artificial intelligence in medicine. Gastrointestinal endoscopy, 92(4), 807–812. https://doi.org/10.1016/j.gie.2020.06.040

[7] Kp Jayatunga, M., Ayers, M., Bruens, L., Jayanth, D., & Meier, C. (2024). How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons. Drug discovery today, 29(6), 104009. https://doi.org/10.1016/j.drudis.2024.104009

[8] Betteridge, I. (2025, April 28). AI-driven biomanufacturing: Revolutionising production and quality in pharmaceuticals. European Pharmaceutical Review. https://www.europeanpharmaceuticalreview.com/article/254402/ai-driven-biomanufacturing-revolutionising-production-and-quality-in-pharmaceuticals/

[9] U.S. Food and Drug Administration, Center for Drug Evaluation and Research. (2023). Artificial intelligence in drug manufacturing: Discussion paper. U.S. Department of Health and Human Services, Food and Drug Administration. https://doi.org/10.1016/j.ijpharm.2021.120554

[10] U.S. Food and Drug Administration, Center for Drug Evaluation and Research. (2023). Artificial intelligence in drug manufacturing: Discussion paper. U.S. Department of Health and Human Services, Food and Drug Administration. https://doi.org/10.1016/j.ijpharm.2021.120554

[11] U.S. Food and Drug Administration, Center for Drug Evaluation and Research. (2023). Artificial intelligence in drug manufacturing: Discussion paper. U.S. Department of Health and Human Services, Food and Drug Administration. https://doi.org/10.1016/j.ijpharm.2021.120554

[12] European Federation of Pharmaceutical Industries and Associations. (2024). Application of AI in a GMP/manufacturing environment: An industry approach (Version 1.0, Final). EFPIA. https://doi.org/10.1016/j.ijpharm.2021.120554

[13] Rajesh, M. V., & Elumalai, K. (2025). The transformative power of artificial intelligence in pharmaceutical manufacturing: Enhancing efficiency, product quality, and safety. Journal of Holistic Integrative Pharmacy, 6(2). https://doi.org/10.1016/j.johip.2025.00013

[14] Ali, K. A., Mohin, S., Mondal, P., Goswami, S., Ghosh, S., & Choudhuri, S. (2024). Influence of artificial intelligence in modern pharmaceutical formulation and drug development. Future Journal of Pharmaceutical Sciences, 10(1), 53. https://doi.org/10.1186/s43094-024-00625-1

[15] Kumar, Y., Koul, A., Singla, R., & Ijaz, M. F. (2022). Artificial intelligence in disease diagnosis: A systematic literature review, synthesizing framework and future research agenda. Journal of Ambient Intelligence and Humanized Computing, 14(7), 8459–8486. https://doi.org/10.1007/s12652-021-03612-z

[16] Das, A. R., Samanta, R., Mishra, R., Sahu, A., Sahoo, S., & Gorain, A. (2025). Application of artificial intelligence (AI) in pharmaceutical industry: In-Depth review. Journal of Neonatal Surgery, 14(26S), 1148-1164. https://doi.org/10.63682/jns.v14i26S.8441

[17] Rajesh, M. V., & Elumalai, K. (2025). The transformative power of artificial intelligence in pharmaceutical manufacturing: Enhancing efficiency, product quality, and safety. Journal of Holistic Integrative Pharmacy, 6(2), 125–135. https://doi.org/10.1016/j.johip.2025.00013

[18] Serrano, D. R., Luciano, F. C., Anaya, B. J., Ongoren, B., Kara, A., Molina, G., Ramirez, B. I., Sánchez-Guirales, S. A., Simon, J. A., Tomietto, G., Rapti, C., Ruiz, H. K., Rawat, S., Kumar, D., & Lalatsa, A. (2024). Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine. Pharmaceutics, 16(10), 1328. https://doi.org/10.3390/pharmaceutics16101328

[19] Rajesh, M. V., & Elumalai, K. (2025). The transformative power of artificial intelligence in pharmaceutical manufacturing: Enhancing efficiency, product quality, and safety. Journal of Holistic Integrative Pharmacy, 6(2), 125-135. https://doi.org/10.1016/j.johip.2025.00013

[20] Dashpute, S. V., Pansare, J. J., Deore, Y. K., Pansare, M. J., Sonawane, P. J., Jadhav, S. P., & Patil, D. M. (2023). Artificial intelligence and machine learning in the pharmaceutical industry. Human Journals, 28(2), 111-131

[21] Choudhary, H., Sharma, A., & Ahuja, D. (2023). Applications of artificial intelligence in pharmaceutical industries. International Journal of Pharmacy & Pharmaceutical Research, 81 (1), 159-164. https://doi.org/10.47583/ijpsrr.2023.v81i01.027

[22] Bhat, V. N., Bharati, S., Bothiraja, C., Sangshetti, J., & Gaikwad, V. (2025). A review on intervention of artificial intelligence in pharmaceutical sector: Revolutionizing drug discovery and manufacturing. Intelligent Pharmacy. https://doi.org/10.1016/j.ipha.2025.04.001

[23] Bhattamisra, S. K., Banerjee, P., Gupta, P., Mayuren, J., Patra, S., & Candasamy, M. (2023). Artificial Intelligence in Pharmaceutical and Healthcare Research. Big Data & Cognitive Computing, 7(1), 10. https://doi.org/10.3390/bdcc7010010 (MDPI)

[24] Sonawane, T. S., & Gaikwad, V. (2022). Artificial intelligence in the pharmaceutical industry – An overview of innovations. International Journal of Research Publication and Reviews, 3(7), 822–834.

[25] Pareek, V., Sharma, L., Kumar, S., & Sharma, V. (2022). Need for artificial intelligence in pharmaceutical industry and its limitations. World Journal of Pharmacology and Toxicology, 5(4), Article 161. https://doi.org/10.4172/wjpt.1000161 (Omics Online Publishing)

[26] Mehta, H., Soni, S., Pant, A., & Sonigara, B. S. (2025). Impact of AI in the pharmaceutical industry. International Journal for Research in Applied Science & Engineering Technology, 13(VI), 254-260. https://doi.org/10.22214/ijraset.2025.71873 (ijraset.com)

[27] Ingle, S. G., Jawarkar, S. G., Bhalerao, S., Gulhane, P., & Belsare, Y. (2023). Review on: Artificial intelligence (AI) in pharmacy. Journal of Emerging Technologies & Innovative Research (JETIR), 10(1), [paper # JETIR2301515].

[28] Devkate, P. S., & Wamane, V. B. (2023). A review – Artificial intelligence in pharma

industry. International Journal in Pharmaceutical Sciences, 1(12), 330-350. https://doi.org/10.5281/zenodo.10373995

[29] Patel, J., Patel, D., & Meshram, D. (2021). Artificial Intelligence in Pharma Industry – A rising concept. Journal of Advancement in Pharmacognosy, 1(2), 1-12. https://doi.org/10.46344/JBINO.2024.v13i04.12

[30] Shinde, P. S., Pawar, A. Y., & Talele, S. G. (2023). The role of artificial intelligence in the pharmaceutical sector: A comprehensive analysis of its application from the discovery phase to industrial implementation. International Journal of Drug Delivery Technology, 13(4), 1578-1584. https://doi.org/10.25258/ijddt.13.4.70

[31] Kant, S., Deepika, & Roy, S. (2025). Artificial intelligence in drug discovery and development: Transforming challenges into opportunities. Discover Pharmaceutical Sciences, 1(1), Article 7. https://doi.org/10.1007/s44395-025-00007-3

[32] Kolluri, S., Lin, J., Liu, R., Zhang, Y., & Zhang, W. (2022). Machine learning and artificial intelligence in pharmaceutical research and development: A review. The AAPS Journal, 24(1), Article 19. https://doi.org/10.1208/s12248-021-00644-3 (PMC)

[33] Nikam, R., Sharma, Y., & Patil, D. (2024). Recent trends of AI in pharmaceutical industries: A review. Open Access Journal of Data Science & Artificial Intelligence, 2(1), Article 16000122. https://doi.org/10.23880/oajda-16000122

[34] Tahilani, P., Swami, H., Goyanar, G., & Tiwari, S. (2022). The era of artificial intelligence in pharmaceutical industries – A review. Research Journal of Science and Technology, 14(3), 183-187. https://doi.org/10.52711/2349-2988.2022.00030

[35] Shah, N., Kumari, M., Sadhu, P., & Talele, C. (2023). Artificial intelligence in pharma industry – A review. Asian Journal of Pharmaceutics, 17(2). https://doi.org/10.22377/ajp.v17i2.4840

[36] Debnath, B., Wilson, S. K., Basu, S., Kompella, S. Y., Singha, R., Sahoo, S. K., Yadav, N., Roy, P., & Kundu, A. (2024). The pharmaceutical industry's future: How artificial intelligence is transforming medicine.

[37] Sharma, N., Rao, N. G. R., Tyagi, T., Sharma, L., Bhardwaj, A., & Pathak, A. (2025). Artificial intelligence—The new frontier in drug discovery: A review. International Journal of Environmental Sciences, 11(11 Suppl), 1022-1039. https://doi.org/10.64252/hdzz3z20 (theaspd.com)

[38] Kolluri, S., Lin, J., Liu, R., Zhang, Y., & Zhang, W. (2022). Machine learning and artificial intelligence in pharmaceutical research and development: A review. The AAPS Journal, 24(1), Article 19. https://doi.org/10.1208/s12248-021-00644-3 (PMC)

[39] Mottaghi-Dastjerdi, N., & Soltany-Rezaee-Rad, M. (2024). Advancements and applications of artificial intelligence in pharmaceutical sciences: A comprehensive review. Iranian Journal of Pharmaceutical Research, 23(1), e150510. https://doi.org/10.5812/ijpr-150510

[40] Dr. Jyothi A. P., Shivaranjini C., & Usha Shree B. N. (2022). AI in pharmaceutical industry – A survey paper. In Proceedings of Futuristic Trends in Artificial Intelligence (Vol. 2, Book 16, Chap. 30, pp. 303–310). IIP Proceedings, Iterative International Publishers. ISBN 978-93-5747-508-2.